HIKMA PHARMACEUTICALS PLC ANNUAL REPORT 2015 Financial Statements Continued Notes to the Consolidated Financial Statements Continued 4.
Segmental reporting For management purposes, the Group is currently organised into three principal operating divisions Branded, Injectables and Generics.
These divisions are the basis on which the Group reports its segmental information.
The Group discloses underlying operating profit as the measure of segmental result, as this is the principal measure used in decision-making and resource allocation by the chief operating decision maker, who is the Groups Chief Executive Officer.
Information regarding the Groups operating segments is reported below.
The following is an analysis of the Groups revenue and results by reportable segment in 2015: BrandedInjectables Generics Others Group Year ended 31 December 2015 $m $m $m $m $m Revenue 570 710 151 9 1,440 Cost of sales 293 261 62 6 622 Gross profit 277 449 89 3 818 Core segment result 118 312 46 5 471 Exceptional items: Integration costs 2 2 Severance costs 5 1 6 Proceeds from legal claims 2 2 Gain from sale of assets, net 6 6 Intangible amortisation other than software 8 8 16 Segment result 105 311 44 5 455 Core unallocated corporate expenses 62 Exceptional items: Acquisition related expenses 12 Unallocated corporate expenses 74 Core operating profit 409 Operating profit 381 Loss impairment of associates 9 Finance income 3 Finance expense 57 Profit before tax 318 Tax 64 Profit for the year 254 Attributable to: Non-controlling interest 2 Equity holders of the parent 252 254 Segment result is defined as operating profit for each segment.
Others mainly comprises Arab Medical Containers Ltd, International Pharmaceutical Research Center Ltd and the chemicals division of Hikma Pharmaceuticals Ltd Jordan.
Unallocated corporate expenses are primarily made up of employee costs, professional fees, travel expenses and donations.
148 148 FINANCIAL STATEMENTS Notes to the Consolidated Financial Statements Continued 4.
Segmental reporting continued For management purposes, the Group is currently organised into three principal operating divisions Branded, Injectables and Generics.
Corporate Branded Injectables Generics and others Group These divisions are the basis on which the Group reports its segmental information.
Segment assets and liabilities 2015 $m $m $m $m $m The Group discloses underlying operating profit as the measure of segmental result, as this is the principal measure used in decision-making Additions to property, plant and equipment cost 24 39 15 7 85 and resource allocation by the chief operating decision maker, who is the Groups Chief Executive Officer.
Remeasurement of property, plant and equipment note 43 1 1 Additions to intangible assets 5 41 8 2 56 Information regarding the Groups operating segments is reported below.
Remeasurement of Intangible assets note 43 8 8 The following is an analysis of the Groups revenue and results by reportable segment in 2015: Total property, plant and equipment and intangible assets net book value 478 532 81 23 1,114 BrandedInjectables Generics Others Group Year ended 31 December 2015 $m $m $m $m $m Depreciation and impairment 22 19 8 2 51 Revenue 570 710 151 9 1,440 Amortisation and impairment including software 9 11 1 1 22 Cost of sales 293 261 62 6 622 Investment in associates and joint ventures 7 7 Gross profit 277 449 89 3 818 Balance sheet Core segment result 118 312 46 5 471 Total assets 1,108 829 165 495 2,597 Exceptional items: Total liabilities 453 397 309 86 1,245 Integration costs 2 2 The following is an analysis of the Groups revenue and results by reportable segment in 2014: Severance costs 5 1 6 Branded Injectables Generics Others Group Proceeds from legal claims 2 2 Year ended 31 December 2014 $m $m $m $m $m Gain from sale of assets, net 6 6 Revenue 551 713 216 9 1,489 Intangible amortisation other than software 8 8 16 Cost of sales 284 282 66 6 638 Segment result 105 311 44 5 455 Gross profit 267 431 150 3 851 Core unallocated corporate expenses 62 Core segment result 111 265 113 5 484 Exceptional items: Exceptional items: Acquisition related expenses 12 Intangible amortisation other than software 9 5 14 Unallocated corporate expenses 74 Segment result 102 260 113 5 470 Core operating profit 409 Core unallocated corporate expenses 57 Operating profit 381 Exceptional items: Loss impairment of associates 9 11 Acquisition related expenses Finance income 3 Unallocated corporate expenses 68 Finance expense 57 Core operating profit 427 Profit before tax 318 Operating profit 402 Tax 64 Loss from associates 6 Profit for the year 254 Finance income 4 Attributable to: Finance expense 38 Non-controlling interest 2 Profit before tax 362 Equity holders of the parent 252 Tax 80 254 Profit for the year 282 Attributable to: Segment result is defined as operating profit for each segment.
Non-controlling interest 4 Others mainly comprises Arab Medical Containers Ltd, International Pharmaceutical Research Center Ltd and the chemicals division of Equity holders of the parent 278 Hikma Pharmaceuticals Ltd Jordan.
282 Unallocated corporate expenses are primarily made up of employee costs, professional fees, travel expenses and donations.
Segment result is defined as operating profit for each segment.
Others mainly comprise Arab Medical Containers Ltd, International Pharmaceutical Research Center Ltd and the chemicals division of Hikma Pharmaceuticals Ltd Jordan.
Unallocated corporate expenses are primarily made up of employee costs, office costs, professional fees, donations and travel expenses.
148 149 149 HIKMA PHARMACEUTICALS PLC ANNUAL REPORT 2015 Financial Statements Continued Notes to the Consolidated Financial Statements Continued 4.
Segmental reporting continued Corporate Branded Injectables Generics and others Group Segment assets and liabilities 2014 $m $m $m $m $m Additions to property, plant and equipment cost 48 31 8 2 89 Acquisition of business property, plant and equipment net book value 53 53 Additions to intangible assets 4 16 4 1 25 Intangible assets arising on acquisition 174 174 Total property, plant and equipment and intangible assets net book value 511 528 70 7 1,116 Depreciation and impairment 22 18 7 2 49 Amortisation and impairment including software 10 13 23 Investment in associates and joint ventures 16 16 Balance sheet Total assets 1,123 770 175 183 2,251 Total liabilities 481 405 92 57 1,035 The following table provides an analysis of the Groups sales by geographical market, irrespective of the origin of the goods services: 2015 2014 $m $m Middle East and North Africa 656 633 United States 697 763 Europe and Rest of the World 82 89 United Kingdom 5 4 1,440 1,489 The top selling markets were as below: 2015 2014 $m $m United States 697 763 Saudi Arabia 162 146 Algeria 113 86 972 995 Included in revenues arising from the Generics and Injectables segments are revenues of approximately $173 million 2014: $221 million which arose from the Groups largest customer which is located in the United States.
The following is an analysis of the total non-current assets excluding deferred tax and financial instruments and an analysis of total assets by the geographical area in which the assets are located: Total non-current assets excluding deferred tax and financial instruments Total assets as at 31 December as at 31 December 2015 2014 2015 2014 $m $m $m $m Middle East and North Africa 577 606 1,174 1,202 Europe 135 141 146 195 United States 390 368 811 648 United Kingdom 63 55 466 206 1,165 1,170 2,597 2,251 150 150
